价格与库存信息目前不能提供
推荐产品
生物源
mouse
品質等級
共軛
biotin conjugate
抗體表格
purified immunoglobulin
抗體產品種類
primary antibodies
無性繁殖
A1, monoclonal
物種活性
human
製造商／商標名
Chemicon®
技術
immunofluorescence: suitable
同型
IgG2a
運輸包裝
wet ice
特異性
Specific for the Influenza A nucleoprotein. Has stronger binding with N1-type Flu A. Has been shown to react with the H5N1 strain. No cross reactivity seen to influenza B or other respiratory viruses.
免疫原
Epitope: nucleoprotein
Influenza A
應用
Detect Influenza A using this Anti-Influenza A Antibody, nucleoprotein, clone A1, biotin-conjugated validated for use in IF.
Immunofluorescence
Optimal dilutions must be determined by end user.
Optimal dilutions must be determined by end user.
Research Category
Infectious Diseases
Infectious Diseases
Research Sub Category
Infectious Diseases - Viral
Infectious Diseases - Viral
外觀
Biotin conjugated purified immunoglobulin. Liquid in 0.01M PBS, pH=7.1, 0.1% Sodium Azide with 15 mg/mL BSA as stabilizer.
儲存和穩定性
Maintain at 2 to 8°C for up to 12 months from date of receipt. Protect from Light.
其他說明
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
法律資訊
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責聲明
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
未找到合适的产品？
试试我们的产品选型工具.
儲存類別代碼
12 - Non Combustible Liquids
水污染物質分類（WGK）
WGK 2
閃點（°F）
Not applicable
閃點（°C）
Not applicable
Felix Broecker et al.
NPJ vaccines, 4, 31-31 (2019-07-26)
Current seasonal influenza virus vaccines only provide limited, short-lived protection, and antigenic drift in the hemagglutinin surface glycoprotein necessitates their annual re-formulation and re-administration. To overcome these limitations, universal vaccine strategies that aim at eliciting broadly protective antibodies to conserved
Sergey Yegorov et al.
Cell reports. Medicine, 3(2), 100509-100509 (2022-03-05)
The induction of broadly neutralizing antibodies (bNAbs) that target the hemagglutinin stalk domain is a promising strategy for the development of "universal" influenza virus vaccines. bNAbs can be boosted in adults by sequential exposure to heterosubtypic viruses through natural infection
Roozbeh Abedini-Nassab et al.
Micromachines, 12(7) (2021-07-03)
Magnetic nanoparticles have attracted significant attention in various disciplines, including engineering and medicine. Microfluidic chips and lab-on-a-chip devices, with precise control over small volumes of fluids and tiny particles, are appropriate tools for the synthesis, manipulation, and evaluation of nanoparticles.
Erin E H Tran et al.
mBio, 7(2), e00257-e00257 (2016-03-24)
Influenza viruses expressing chimeric hemagglutinins (HAs) are important tools in the quest for a universal vaccine. Using cryo-electron tomography, we have determined the structures of a chimeric HA variant that comprises an H1 stalk and an H5 globular head domain
An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses.
David J Holthausen et al.
Immunity, 46(4), 587-595 (2017-04-20)
Although vaccines confer protection against influenza A viruses, antiviral treatment becomes the first line of defense during pandemics because there is insufficient time to produce vaccines. Current antiviral drugs are susceptible to drug resistance, and developing new antivirals is essential.
Active Filters
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门
